Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone
- PMID: 3079654
- DOI: 10.1007/BF02556596
Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone
Abstract
Serum bone Gla-protein (sBGP) was measured in 32 patients with untreated Paget's disease of bone. Despite clinical and biological symptoms of active disease in all patients, sBGP was normal in 13/32 patients (41%). There was a striking discrepancy between the moderate increase of sBGP above normal values (11.4 +/- 4.5 vs 6.0 +/- 2.1 ng/ml) and the marked increase of both serum alkaline phosphatase (sAP) and urinary hydroxyproline (uOHP). sBGP was weakly correlated with sAP (r = 0.50, p less than 0.01), uOHP (r = 0.48, p less than 0.01) and with the extension of the disease (r = 0.48, p less than 0.01). We conclude that sBGP is not a sensitive marker of bone turnover in patients with Paget's disease of bone, and should be interpreted with caution in this condition.
Similar articles
-
Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.Scand J Clin Lab Invest. 1989 May;49(3):279-85. Scand J Clin Lab Invest. 1989. PMID: 2787049
-
Clinical usefulness of serum tartrate-resistant acid phosphatase in Paget's disease of bone: correlation with other biochemical markers of bone remodelling.Calcif Tissue Int. 1991 Jul;49(1):14-6. doi: 10.1007/BF02555896. Calcif Tissue Int. 1991. PMID: 1893290
-
Correlation between serum osteocalcin and 24,25-dihydroxyvitamin D levels in Paget's disease of bone.J Clin Endocrinol Metab. 1991 Feb;72(2):462-6. doi: 10.1210/jcem-72-2-462. J Clin Endocrinol Metab. 1991. PMID: 1991815
-
Biochemical markers of bone turnover in Paget's disease of bone.Bone. 1999 May;24(5 Suppl):49S-50S. doi: 10.1016/s8756-3282(99)00053-8. Bone. 1999. PMID: 10321928 Review. No abstract available.
-
[Biological and isotope explorations in Paget's disease of bone].Rhumatologie. 1971 Apr;23(4):119-39. Rhumatologie. 1971. PMID: 4254981 Review. French. No abstract available.
Cited by
-
Clinical value of the measurement of bone remodelling markers in primary hyperparathyroidism.J Endocrinol Invest. 1989 Sep;12(8):537-42. doi: 10.1007/BF03350755. J Endocrinol Invest. 1989. PMID: 2592739
-
Treatment of patients with Paget's disease of bone.Drugs. 1999 Nov;58(5):823-30. doi: 10.2165/00003495-199958050-00005. Drugs. 1999. PMID: 10595863 Review.
-
Markers of bone turnover for the management of patients with bone metastases from prostate cancer.Br J Cancer. 2000 Feb;82(4):858-64. doi: 10.1054/bjoc.1999.1012. Br J Cancer. 2000. PMID: 10732759 Free PMC article.
-
Emerging strategies and therapies for treatment of Paget's disease of bone.Drug Des Devel Ther. 2011;5:225-39. doi: 10.2147/DDDT.S11306. Epub 2011 Apr 26. Drug Des Devel Ther. 2011. PMID: 21607019 Free PMC article. Review.
-
beta 2-Microglobulin in Paget's bone disease.Calcif Tissue Int. 1994 May;54(5):389-91. doi: 10.1007/BF00305525. Calcif Tissue Int. 1994. PMID: 8062156
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous